Iovance Biotherapeutics, Inc. (IOVA) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2013
Loading P/E history...
IOVA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Iovance Biotherapeutics, Inc. (IOVA) trades at a price-to-earnings ratio of -3.3x, with a stock price of $3.55 and trailing twelve-month earnings per share of $-0.85.
The current P/E is 191% below its 5-year average of 3.6x. Over the past five years, IOVA's P/E has ranged from a low of 3.6x to a high of 3.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, IOVA trades at a 115% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, IOVA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IOVA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IOVA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 15.5Lowest | -Best | +1747%Best | |
| $39B | 127.0 | -Best | +207% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
IOVA Historical P/E Data (2013–2013)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2013 Q1 | Sun Mar 31 2013 00:00:00 GM | $6.00 | $1.67 | 3.6x | +0% |
Average P/E for displayed period: 3.6x
See IOVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IOVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IOVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIOVA — Frequently Asked Questions
Quick answers to the most common questions about buying IOVA stock.
Is IOVA stock overvalued or undervalued?
IOVA trades at -3.3x P/E, below its 5-year average of 3.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does IOVA's valuation compare to peers?
Iovance Biotherapeutics, Inc. P/E of -3.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is IOVA's PEG ratio?
IOVA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2013.